GLP-1 medications, like Ozempic and Wegovy, mimic natural hormones in the body that regulate blood sugar and insulin levels. They’re used to treat type 2 diabetes and obesity. These drugs curb the ...

ReShape Lifesciences Inc. ( NASDAQ: RSLS) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Michael Miller - Rx Communications Paul Hickey - President and CEO Thomas Stankovich - CFO ...

Amid a decade-high surge in drug shortages, the American Medical Association has adopted new policy measures aimed at addressing the crisis.

It’s hard to remember a time before Ozempic, Wegovy, and other injectable drugs referred to as GLP-1 receptor agonists (that ...

The rise in type 2 diabetes cases globally presents opportunities for growth in the market for GLP-1 drugs like Ozempic and ...

Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.

Thank you for standing by. My name is John, and I’ll be your conference operator today. At this time I would like to welcome everyone to the Allurion Third Quarter Earnings Call. All lines have been ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

After Altimmune (ALT) reported Q3 results and provided an update focused on its lead program pemvidutide, a GLP-1/glucagon dual receptor ...

Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...

Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...

Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today shared more data on the challenges Americans are facing when trying to access branded GLP-1 ...